Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Gilead is bucking the trend in IL-12, entering the space after seeing rivals such as AstraZeneca and Bristol Myers Squibb retreat from the cytokine.
Nick Paul Taylor
Mar 28, 2024 8:08am
Ferrer offers $122M biobucks for ex-US license to Verge ALS drug
Mar 25, 2024 8:16am
Hansoh signs $690M ADC pact with fellow Chinese biotech Biotheus
Mar 15, 2024 8:35am
Astellas puts the cork back in $350M Xork deal with Cartesian
Mar 14, 2024 10:41am
Merck bets up to $1B on Pearl's 'smart' biologics
Mar 12, 2024 8:00am
Boehringer pays €25M for option to Sosei’s schizophrenia drug
Mar 11, 2024 9:10am